Background/Aims: Stroke and aphasia rehabilitation aims to improve people’s quality of life. Yet, scales for measuring health-related quality of life in stroke typically exclude people with aphasia. They are also primarily available in English. An exception is the 39-item generic version of the Stroke and Aphasia Quality of Life Scale (SAQOL-39g). This scale has been tested with people with aphasia; it has been adapted for use in many countries including Greece. The aim of this study was to examine the psychometric properties of the Greek SAQOL-39g. Methods: An interview-based psychometric study was carried out. Participants completed: receptive subtests of the Frenchay Aphasia Screening Test, the Greek SAQOL-39g, the 12-item General Health Questionnaire, the Frenchay Activities Index, the Montreal Cognitive Assessment and the Barthel Index. Results: 86 people took part; 26 provided test-retest reliability data. The Greek SAQOL-39g demonstrated excellent acceptability (minimal missing data; no floor/ceiling effects), test-retest reliability [intraclass correlation coefficient = 0.96 (overall scale), 0.83–0.99 (domains)] and internal consistency [Cronbach’s alpha = 0.96 (overall scale), 0.92–0.96 (domains)]. There was strong evidence for convergent [r = 0.53–0.80 (overall scale), 0.54–0.89 (domains)] and discriminant validity [r = 0.52 (overall scale), 0.04–0.48 (domains)]. Conclusion: The Greek SAQOL-39g is a valid and reliable scale. It is a promising measure for use in stroke and aphasia treatment prioritization, outcome measurement and service evaluation.

Keywords:
Health-related quality of life, Stroke, Stroke and Aphasia Quality of Life Scale, Greece
1.
Bullinger M, Anderson R, Cella D, Aaronson N: Developing and evaluating cross-cultural instruments: from minimum requirements to optimal models. Qual Life Res 1993;2:451–459.
2.
Berzon R, Hays RD, Shumaker SA: International use, application and performance of health-related quality of life instruments. Qual Life Res 1993;2:367–368.
3.
Hays RD, Anderson R, Revicki D: Psychometric considerations in evaluating Health-Related Quality of Life measures. Qual Life Res 1993;2:441–449.
4.
Royal College of Physicians: National Clinical Guidelines for Stroke. Prepared by the Intercollegiate Working Party for Stroke. London, Royal College of Physicians, 2000.
5.
Royal College of Physicians: National Clinical Guidelines for Stroke, ed 3. Prepared by the Intercollegiate Working Party for Stroke. London, Royal College of Physicians, 2008.
6.
Engelter ST, Gostynski M, Papa S, Frei M, Born C, Ajdacic-Gross V, et al: Epidemiology of aphasia attributable to first ischemic stroke: incidence, severity, fluency, etiology, and thrombolysis. Stroke 2006;37:1379–1384.
7.
Wade DT: Stroke (acute cerebrovascular disease); in Stevens A, Raftery J (eds): Health Care Needs Assessment. Oxford, Radcliffe Medical Press, 1994.
8.
Cruice M, Worrall L, Hickson L, Murison R: Measuring quality of life: comparing family members’ and friends’ ratings with those of their aphasic partners. Aphasiology 2005;19:111–129.
9.
Hilari K, Wiggins RD, Roy P, Byng S, Smith SC: Predictors of health-related quality of life (HRQL) in people with chronic aphasia. Aphasiology 2003;17:365–381.
10.
Lam JM, Wodchis WP: The relationship of 60 disease diagnoses and 15 conditions to preference-based health-related quality of life in Ontario hospital-based long-term care residents. Med Care 2010;48:380–387.
11.
Hilari K, Needle J, Harrison K: What are the important factors in health-related quality of life for people with aphasia? A systematic review. Arch Phys Med Rehabil 2012;93(Suppl 1):S83–S95.
12.
De Haan R, Horn J, Limburg M, Van Der MJ, Bossuyt P: A comparison of five stroke scales with measures of disability, handicap, and quality of life. Stroke 1993;24:1178–1181.
13.
Patrick DL, Erickson P: Assessing health-related quality of life for clinical decision making; in Walker SR (ed): Quality of Life Assessment: Key issues in the 1990s. Dordrecht, Kluwer Academic Publishers, 1993, pp 11–63.
14.
Mayou R, Bryant B: Quality of life in cardiovascular disease. BMJ 1993;69:460–466.
15.
Duncan PW, Wallace D, Lai SM, Johnson D, Embretson S, Laster LJ: The Stroke Impact Scale version 2.0. Evaluation of reliability, validity, and sensitivity to change. Stroke 1999;30:2131–2140.
16.
Williams L, Weinberger M, Harris LE, Clark DO, Biller J: Development of a stroke-specific quality of life scale. Stroke 1999;30:1362–1369.
17.
Hilari K, Byng S, Lamping DL, Smith SC: Stroke and Aphasia Quality of Life Scale-39 (SAQOL-39). Evaluation of acceptability, reliability, and validity. Stroke 2003;34:1944–1950.
18.
Hilari K, Lamping DL, Smith SC, Northcott S, Lamb A, Marshall J: Psychometric properties of the Stroke and Aphasia Quality of Life Scale (SAQOL-39) in a generic stroke population. Clinical Rehabilitation 2009;23:544–557.
19.
Posteraro L, Formis A, Bidini C, Grassi E, Curti M, Bighi M, Agosti M, Franceschini M: Aphasia quality of life: reliability of the Italian version of SAQOL-39. Eura Medicophys 2004;40:257–262.
20.
Manders E, Dammekens E, Leemans I, Michiels K: Evaluation of quality of life in people with aphasia using a Dutch version of the SAQOL-39. Disabil Rehabil 2010;32:173–182.
21.
Kartsona A, Hilari K: Quality of life in aphasia: Greek adaptation of the stroke and aphasia quality of life scale – 39 item (SAQOL-39). Eura Medicophys 2007;43:27–35.
22.
Lata-Caneda MC, Pineiro-Temprano M, Garcia-Armesto I, Barrueco-Egido JR, Meijide-Failde R: Spanish adaptation of the Stroke and Aphasia Quality of Life Scale-39 (SAQOL-39). Eur J Phys Rehabil Med 2009;45:379–384.
23.
Enderby P, Wood V, Wade D: Frenchay Aphasia Screening Test. Windsor, NFER-Nelson, 1987.
24.
Goldberg DP: The Detection of Psychiatric Illness by Questionnaire. London, Oxford University Press, 1972.
25.
Wade DT, Legh-Smith J, Langton Hewer R: Social activities after stroke: measurement and natural history using the Frenchay Activities Index. Int Rehabil Med 1985;7:176–181.
26.
Nasreddine Z: Montreal Cognitive Assessment (MoCA). www.mocatest.org. 2004.
27.
Mahoney FI, Wood OH, Barthel DW: Rehabilitation of chronically ill patients: the influence of complications on the final goal. South Med J 1958;51:605–609.
28.
Garyfallos G, Karastergiou A, Adamopoulou A, Moutzoukis C, Alagiozidou E, Mala D, Garyfallos A: Greek version of the General Health Questionnaire: accuracy of translation and validity. Acta Psychiatr Scand 1991;84:371–378.
29.
Kounti F, Tsolaki M, Eleftheriou M, Agogiatou C, Karagiozi K, Bakoglidou E, et al: Administration of Montreal Cognitive Assessment (MoCA) test in Greek elderly patients with mild cognitive impairment and patients with dementia. 9th European Conference on Psychological Assessment and 2nd International Conference of the Psychological Society of Northern Greece, 2007, pp 155–156.
30.
Johnson G, Burvill PW, Anderson CS, Jamrozik K, Stewart-Wynne EG, Chakera TM: Screening instruments for depression and anxiety following stroke: experience in the Perth community stroke study. Acta Psychiatr Scand 1995;91:252–257.
31.
Hackett ML, Anderson CS, House AO: Management of depression after stroke: a systematic review of pharmacological therapies. Stroke 2005;36:1092–1097.
32.
Nasreddine ZS, Philips NA, Bedirian V, Charbonneau S, Whitehead V, Colin I, Cummings JL, Chertkow H: The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695–699.
33.
Clarke PJ, Black SE, Badley EM, Lawrence JM, Williams JI: Handicap in stroke survivors. Disabil Rehabil 1999;21:116–123.
34.
Jonkman EJ, de Weerd AW, Vrijens NL: Quality of life after a first ischemic stroke. Long-term developments and correlations with changes in neurological deficit, mood and cognitive impairment. Acta Neurol Scand 1998;98:169–175.
35.
Lamping DL, Schroter S, Marquis P, Marrel A, Duprat-Lomon I, Sagnier P: The Community-Acquired Pneumonia Symptom questionnaire: a new, patient-based outcome measure to evaluate symptoms in patients with community-acquired pneumonia. Chest 2002;122:920–929.
36.
Carod-Artal J, Egido JA, González JL, Varela de Seijas E: Quality of life among stroke survivors evaluated 1 year after stroke: experience of a Stroke Unit. Stroke 2000;31:2995–3000.
37.
Kwa VI, Limburg M, de Haan R: The role of cognitive impairment in the quality of life after ischaemic stroke. J Neurol 1996;243:599–604.
38.
Streiner DL, Norman GR: Health Measurement Scales. A Practical Guide to Their Development and Use, ed 2. New York, Oxford University, 1995.
39.
Hilari K: The impact of stroke: are people with aphasia different to those without? Disabil Rehabil 2011;33:211–218.
40.
Elman RJ, Bernstein-Ellis E: Psychosocial aspects of group communication treatment: preliminary findings. Semin Speech Lang 1999;20:65–72.
41.
Ross A, Winslow I, Marchant P, Brumfitt S: Evaluation of communication, life participation and psychological well-being in chronic aphasia: the influence of group intervention. Aphasiology 2006;20:427–448.
42.
Vickers CP: Social networks after the onset of aphasia: the impact of aphasia group attendance. Aphasiology 2010;24:902–913.
43.
Best W, Greenwood A, Grassly J, Hickin J: Bridging the gap: can impairment-based therapy for anomia have an impact at the psycho-social level? Int J o Lang Commun Disord 2008;43:390–407.
44.
Simmons-Mackie N, Raymer A, Armstrong E, Holland A, Cherney LR: Communication partner training in aphasia: a systematic review. Arch Phys Med Rehabil 2010;91:1814–1837.
45.
Hilari K, Byng S: Health-related quality of life in people with severe aphasia. Int J Lang Commun Disord 2009;44:193–205.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.